# IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma

> **NIH NIH R37** · WASHINGTON UNIVERSITY · 2020 · $348,844

## Abstract

The prognosis for pancreatic cancer patients remains dismal. Effective therapy is clearly an unmet medical need
for these patients. Aside from surgery which benefits a small fraction of patients, current standard treatment
consists of strong chemotherapy that is highly toxic and with less than 50% chance of working. For those who
initially benefit from chemotherapy, rapid progression is inevitable. The promise of immunotherapy, while already
realized in other cancer types, has failed to show benefit for pancreatic cancer patients. Therapeutic
breakthrough must therefore come from novel discoveries in the biology of pancreatic cancer. We now recently
found, for the first time in literature, that pancreatic cancer cells “armored” themselves by activating the innate
immunity, a self-defense mechanism that is usually summoned when cells are injured or invaded by
microorganisms. In doing so pancreatic cancer cells become highly aggressive and resistant to
chemotherapeutics. Our approach is to “deactivate” such defense mechanism in pancreatic cancer cells by
inhibiting Interleukin-1 Receptor-Associated Kinase 4 (IRAK4), the master switch that controls the innate immune
pathway. By doing so we found that pancreatic cancer cells become greatly weakened and are much more
vulnerable to chemotherapy. On this premise we have now made further potentially impactful findings that we
plan to confirm and pursue in the following three aims:
 1. Aim 1: We found that presence of IRAK4 is essential for supporting transformed growth and cellular
 signaling driven by oncogenic KRAS, a genetic event that is present in almost all pancreatic cancer. We
 will explore the mechanistic detail and determine whether loss of IRAK4 will impede KRAS-driven
 pancreatic tumorigenesis using human pancreatic cancer cell lines and state-of-the-art genetic mouse
 models. If shown to be true, these results could have impact on other KRAS-mutant cancer types.
 2. Aim 2: We have generated an IRAK4-deficient pancreatic cancer mouse model that we plan to
 characterize to understand the consequence of global IRAK4 loss, as will happen with pharmacologic
 inhibition, in pancreatic cancer progression. In addition, we will specifically study the role of immune
 IRAK4 in pancreatic cancer growth, which will yield clinically useful information if IRAK4 inhibitors are
 advanced into clinical trials in the future.
 3. Aim 3: Our preliminary data shows that IRAK4 inhibition renders immunotherapy effective in genetic
 mouse model. In this aim we will test two novel, highly potent IRAK4 inhibitors, with the ultimate goal of
 translating these findings into clinical trials.

## Key facts

- **NIH application ID:** 9850548
- **Project number:** 5R37CA219697-03
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Kian H Lim
- **Activity code:** R37 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $348,844
- **Award type:** 5
- **Project period:** 2018-02-08 → 2023-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9850548

## Citation

> US National Institutes of Health, RePORTER application 9850548, IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma (5R37CA219697-03). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9850548. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*